Improving treatment options for inflammatory bowel disease using small molecules
Optimization of small molecule immunomodulators as combination therapy for IBD
This study is looking for new ways to improve treatment for inflammatory bowel disease (IBD) by creating small molecules that work better with your immune system, aiming to find combinations that help manage the condition with fewer side effects than current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weill Medical Coll of Cornell Univ NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11072010 on NIH RePORTER |
What this research studies
This research focuses on developing new small molecule immunomodulators to enhance treatment for inflammatory bowel disease (IBD). It aims to identify effective combinations of therapies that target specific immune cell receptors, which could lead to better management of the disease. By utilizing a novel platform called Small Molecules from Antibody Pharmacophores (SMAPs), the researchers will create small molecules that minimize the risk of adverse effects compared to current protein-based therapies. This approach seeks to address the high rates of treatment failure seen with existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with inflammatory bowel disease who have not responded adequately to existing treatments.
Not a fit: Patients with mild or well-controlled inflammatory bowel disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide more effective and safer treatment options for patients with inflammatory bowel disease.
How similar studies have performed: While the approach of using small molecules for immunomodulation is innovative, similar strategies targeting immune pathways have shown promise in other inflammatory conditions.
Where this research is happening
New York, United States
- Weill Medical Coll of Cornell Univ — New York, United States (Active)
Researchers
- Principal investigator: Gabr, Moustafa — Weill Medical Coll of Cornell Univ
- Study coordinator: Gabr, Moustafa
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.